The impact of the nerve growth factor on the number of MYCC, MYCN oncogene copies in human medulloblastoma cells
https://doi.org/10.18027/2224-5057-2019-9-1-22-28
Abstract
Introduction: The search for new molecular targets for chemotherapy of malignancies, particularly pediatric brain tumors, is a relevant issue of modern oncology. MYC expression and amplification is often observed in brain tumors, which is an unfavorable prognostic factor. Many oncogenic processes are regulated by some growth factors including the nerve growth factor (NGF).
Purpose: To study the changes in the number of MYCCand MYCN‑gene copies in MB cells exposed to the NGF.
Material and methods: The impact of the NGF on the number of MYCC‑, MYCN oncogene copies in the primary human medulloblastoma cell culture was assessed using the method of fluorescence in situ hybridization.
Results: Exposure to the NGF was shown to decrease the number of MB cells containing 6, 8 copies of MYCN oncogenes and 3, 8 copies of MYCC oncogene. The NGF was also shown to increase the number of tumor cells that contain a double set of copies of both oncogenes. There was a statistically significant (p<0.0001) negative correlation (r=–0.65) between the average number of MYCC oncogene copies and the NGF cytotoxicity index.
Conclusion: The increased number of oncogene copies reduces the susceptibility of MB cells to the growth factor.
About the Author
A. N. Chernov
Federal State Budgetary Institution V. A. Almazov National Medical Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Alexandr N. Chernov, researcher, Preclinical and Translational Research Center, Institute of Experimental Medicine
Saint Petersburg
References
1. Crawford J. R., MacDonald T. J., Packer R. J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007. Vol. 6 (12). P. 1073–1085.
2. Carlotti C. G. Jr., Smith C., Rutka J. T. The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg. Rev 2008. Vol. 31 (4). P. 359–368.
3. Pizer B. L., Clifford S. C. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br. J. Neurosurg. 2009. Vol. 23 (4). P. 364–375.
4. Packer R. J., Cogen P., Vezina G., Rorke L. B. Medulloblastoma: clinical and biologic aspects. Neurooncol. 1999. Vol. 1 (3). P. 232–250.
5. Pfister S., Remke M., Benner A. et al. Outcome prediction in pediatric medulloblastoma based on DNA copy number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 2009. Vol. 27 (10). P. 1627–1636.
6. Lamont J. M., McManamy C. S., Pearson A. D. et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin. Cancer Res. 2004. Vol. 10 (16). P. 5482–5493.
7. Pan E., Pellarin M., Holmes E. et al. Isochromosome 17q is a negative prognostic factor in poor risk childhood medulloblastoma patients. Clin. Cancer Res. 2005. Vol. 11 (13). P. 4733–4740.
8. Lo K. C., Ma C., Bundy B. N. et al. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin. Cancer Res. 2007. Vol. 13 (23). P. 7022–7028.
9. Friedrich C. von Bueren A. O., von Hoff K. et al. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. Eur. J. Cancer. 2012. Vol. 49 (12). P. 893–903.
10. Sandberg A. A., Stone J. F. Medulloblastoma, primitive neuroectodermal tumors, and pineal tumors. The Genetics and Molecular Biology of Neural Tumors Totowa, New York: Humana Press, 2008. Ch. 8. 343–430.
11. Kool M., Koster J., Bunt J. et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008. Vol. 3 (8): e3088.
12. Rutkowski S., von Bueren A., Hoff K. et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trail HIT»91. Clin. Cancer Res. 2007. Vol. 13 (9). P. 2651–2657.
13. Monje M., Beachy P. A., Fisher P. G. Hedgehogs, filies, Wnta and mycs: the time has come for many things in medulloblastoma. J. of Clin. Oncol. 2011. Vol. 29 (11). P. 1395–1398.
14. Свирновский А. И., Пасюков В. В. Молекулярные основы феномена химиои радиорезистентности при опухолевых процессах. Мед. новости. 2007. № 11. С. 7–19.
15. von Bueren A. O., Oehler C., Shalaby T. et al. c MYC expression sensitizes medulloblastoma cells to radioand chemotherapy and has no impact on response in medulloblastoma patients BMC Cancer. 2011. 11: 74.
16. Ponzielli R., Katz S., Barsyte Lovejoy D. et al. Cancer therapeutics: targeting the dark side of myc. Eur. J. Cancer. 2005. Vol. 41 (16). P. 2485–2501.
17. Ryan S. L., Schwalbe E. C., Cole M. et al. MYC family amplification and clinical risk factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica. 2012. Vol. 123 (4). P. 501–513.
18. Shalaby T., von Bueren A. O., Hürlimann M. L. et al. Disabling c MYC in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G quadruplex interactive agent S2T1 6OTD Mol. Cancer Ther. 2010. Vol. 9 (1). P. 167–179.
19. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001. Vol. 169 (2). P. 107–114.
20. Tacconelli A., Farina AR., Cappabianca L. et al. TrkA alternative splicing: a regulated tumor promoting switch in human neuroblastoma. Cancer Cell. 2004. Vol. 6 (4). P. 347–360.
21. Божкова В. П. Брежестовский П. Д., Буравлев В. П. и др. Руководство по культивированию нервной ткани. Ме тоды. Техника. Проблемы. Под ред.: Б. П. Вепринцева, И. В. Викторова, Б. Я. Вильнера М.: Наука, 1988. 318 с.
22. Калюнов В. Н. Фактор роста нервной ткани. Мн.: Наука и техника, 1984. 216 с.
23. Миронов А. Н., Бунатян Н. Н., Васильева А. Н. и др. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. Под ред.: Муляра А. Г., Чиченкова О. Н. М.: Гриф и К, 2012. 944 с.
24. Zitterbart K., Filkova H., Tomasikova L. et al. Low level copy number changes of myc genes have a prognostic impact in medulloblastoma. J. Neurooncol. 2011. Vol. 102 (1). P. 25–33.
25. Nakagawara A., Brodeur G. M. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Europ. J. Cancer. 1997. Vol. 33 (12). P. 2050–2053.
26. Woo C. W., Lucarelli E., Thiele C. J. NGF activation of TrkA decreases N myc expression via MAPK path leading to a decrease in neuroblastoma cell number. Oncogene. 2004. Vol. 23 (8). P. 1522–1530.
27. Свирновский А. И., Григорович С. А. Плейотропная резистентность опухолевых клеток к терапевтическим воздействиям при В клеточных лимфопролиферативных заболеваниях. Мед. новости. 2005. № 9. С. 5–16.
28. Shimada H., Nakagawa A., Peters J. et al. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer. 2004. Vol. 101 (8). P. 1873–1881.
29. Caiazzo M., Colucci D»Amato L., Esposito M. T. et al. Transcription factor KLF7 regulates differentiation of neuroectodermal and mesodermal cell lineages. Exp. Cell Res. 2010. Vol. 316 (14). P. 2365–2376.
30. Li C., Macdonald J. I., Hryciw T. et al. Nerve growth factor activation of the TrkA receptor induces cell death, by macropinocytosis, in medulloblastoma Daoy cells. J. Neurochem. 2010. Vol. 112 (4). P. 882–899.
31. Rutkowski S., von Bueren A., von Hoff K. et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trail HIT»91. Clin. Cancer Res. 2007. Vol. 13 (9). P. 2651–2657.
32. Свирновский А. И. Резистентность опухолевых клеток к терапевтическим воздействиям как медико биологиче ская проблема. Мед. новости. 2011. № 2. С. 30–38.
Review
For citations:
Chernov A.N. The impact of the nerve growth factor on the number of MYCC, MYCN oncogene copies in human medulloblastoma cells. Malignant tumours. 2019;9(1):22-28. (In Russ.) https://doi.org/10.18027/2224-5057-2019-9-1-22-28
Views:
970
Email this article 